BioTuesdays

Tag - Thomas Shrader

Athira Pharma

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

Sigilon Therapeutics

BTIG starts Sigilon Therapeutics at buy; PT $14

BTIG launched coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a “buy” rating and price target of $14. The stock closed at $5.38 on Oct. 28. Sigilon is developing shielded living therapeutics (SLTs) as a “functional...

Gain-Therapeutics-Logo

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

oncosec

BTIG starts OncoSec Medical at buy; PT $10

BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...

Silence-Therapeutics-Logo

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

Mersana Therapeutics Logo

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

Cue Biopharma Logo

BTIG starts Cue Biopharma at buy; PT $26

BTIG launched coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $26 price target. The stock closed at $15.51 on Jan. 27. Cue Biopharma exploits signals naturally provided by dendritic cells (DCs) to...

Alector

BTIG starts Alector at buy; PT $28

BTIG initiated coverage of Alector (NASDAQ:ALEC) with a “buy” rating and $28 price target. The stock closed at $15.80 on Nov. 20. Alector is focused on the immune system of the brain as a major player in...

Sutra-Biopharma-Logo

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

Gritstone Oncology

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...